Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey
Pierre-André Jarrot,Adrien Mirouse,Sébastien Ottaviani,Simon Cadiou,Jean-Hugues Salmon,Eric Liozon,Simon Parreau,Martin Michaud,Benjamin Terrier,Pierre-Edouard Gavand,Ludovic Trefond,Virginie Lavoiepierre,Jeremy Keraen,Daniel Rekassa,Bastien Bouldoires,Thierry Weitten,Damien Roche,Antoine Poulet,Caroline Charpin,Vincent Grobost,Marion Hermet,Magali Pallure,Chloe Wackenheim,Ludovic Karkowski,Pierre Grumet,Thomas Rogier,Nabil Belkefi,Vincent Pestre,Emilie Broquet,Amélie Leurs,Sophie Gautier,Valérie Gras,Pierre Gilet,Jan Holubar,Nadia Sivova,Nicolas Schleinitz,Jean-Marc Durand,Brice Castel,Alexandre Petrier,Robin Arcani,Baptiste Gramont,Philippe Guilpain,Hubert Lepidi,Pierre-Jean Weiller,Joelle Micallef,David Saadoun,Gilles Kaplanski,Pierre-André JarrotAdrien MirouseSébastien OttavianiSimon CadiouJean-Hugues SalmonEric LiozonSimon ParreauMartin MichaudBenjamin TerrierPierre-Edouard GavandLudovic TrefondVirginie LavoiepierreJeremy KeraenDaniel RekassaBastien BouldoiresThierry WeittenDamien RocheAntoine PouletCaroline CharpinVincent GrobostMarion HermetMagali PallureChloe WackenheimLudovic KarkowskiPierre GrumetThomas RogierNabil BelkefiVincent PestreEmilie BroquetAmélie LeursSophie GautierValérie GrasPierre GiletJan HolubarNadia SivovaNicolas SchleinitzJean-Marc DurandBrice CastelAlexandre PetrierRobin ArcaniBaptiste GramontPhilippe GuilpainHubert LepidiPierre-Jean WeillerJoelle MicallefDavid SaadounGilles Kaplanskia Department of Internal Medicine and Clinical Immunology,Hôpital de La Conception,Assistance Publique-Hôpitaux de Marseille (AP-HM),Marseille,Franceb Centre for Cardiovascular and Nutrition Research (C2VN),INRA 1260,INSERM UMR_S1263,Aix-Marseille University,Marseille,Francec Department of Internal Medicine and Clinical Immunology,Centre de Référence des Maladies Auto-Immunes Systémiques Rares,Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose inflammatoire (CEREMAIA),Sorbonne Universités,Paris,Franced INSERM,UMR_S 959 Lab,Immunology,Immunotherapeutics,Paris,Francee DMU 3ID,AP-HP,Groupe Hospitalier Pitié-Salpêtrière,Paris,Francef Department of Rheumatology,DMU Locomotion,Hôpital Bichat-Claude Bernard,APHP,Université de Paris,Paris,Franceg Department of Rheumatology,CHU de Rennes,Université de Rennes 1,Rennes,Franceh Department of Rheumatology,Hôpital de La Maison Blanche,Université de Reims,Reims,Francei Department of Internal Medicine,Hôpital Universitaire de Limoges,Limoges,Francej Department of Internal Medicine,Clinique Saint-Exupery,Toulouse,Francek National Referral Center for Rare Systemic Autoimmune Disease,Hôpital Cochin,Assistance Publique-Hôpitaux de Paris (AP-HP),Centre,Université Paris Cité,Paris,Francel Department of Internal Medicine,Clinique Rhena,Strasbourg,Francem Department of Internal Medicine,Hôpital Gabriel Montpied,Clermont-Ferrand,Francen Department of Internal Medicine,Hôpital de Cornouaille,Quimper,Franceo Department of Rehabilitation,Centre Thermal,Greoux Les Bains,Francep Department of Internal Medicine,Hôpital Louis Pasteur,Colmar,Franceq Department of Internal Medicine,Hôpital des Alpes du Sud,Gap,Francer Department of Rheumatology,Hôpital Saint-Joseph,Marseille,Frances Department of Internal Medicine,Hôpital Saint-Joseph,Marseille,Francet Department of Internal Medicine,Hôpital Estaing,Clermont-Ferrand,Franceu Department of Internal Medicine,Hôpital de Vichy,Vichy,Francev Department of Rheumatology,Hôpital de Cannes Simone Veil,Cannes,Francew Department of Internal Medicine,Medipole Hôpital Privé,Villeurbanne,Francex Department of Internal Medicine,Hôpital d'Instruction des Armées Sainte-Anne,Toulon,Francey Department of Internal Medicine and Systemic Disease,Hôpital François Mitterand,Dijon,Francez Department of Internal Medicine,CH de Melun,Melun,Franceaa Department of Internal Medicine and Infectious Disease,CH d'Avignon,Avignon,Francebb General Practitioner,Bordeaux,Francecc Department of Internal Medicine and Infectious Disease,CH de Dunkerque,Dunkerque,Francedd Department of Pharmacology,centre régional de pharmacovigilance Nord Pas de Calais,CHRU de Lille,Lille,Franceee Department of Clinical Pharmacology,Centre régional de pharmacovigilance,service de pharmacologie clinique,CHU Amiens-Picardie,Amiens,Franceff Regional Center of Pharmacovigilance,CHRU de Nancy,Hôpital Central,Nancy,Francegg Department of Internal Medicine,CHU de Nîmes,Nîmes,Francehh Department of Internal Medicine,CH de Tourcoing,Tourcoing,Franceii Department of Internal Medicine,Hôpital de La Timone,Assistance Publique-Hôpitaux de Marseille (AP-HM),Marseille,Francejj Department of Internal Medicine,CH de Tarbes,Tarbes,Francekk General Practitioner,Roquebrune sur Argens,Francell Department of Internal Medicine and Therapeutics Department,Hôpital de La Timone,Marseille,Francemm Department of Internal Medicine,CHU de Saint-Etienne,Saint-Etienne,Francenn Department of Internal Medicine,CHU Saint-Eloi,Montpellier,Franceoo Pathological Laboratory,Hôpital de La Timone,Assistance Publique-Hôpitaux de Marseille (AP-HM),Marseille,Francepp Department of Onco-Hematology,Institut Paoli-Calmettes,Marseille,Franceqq Department of Clinical Pharmacology and pharmacosurveillance,Regional Pharmacovigilance Center of Marseille,Hôpital de La Timone,Assistance Publique-Hôpitaux de Marseille (AP-HM),Marseille,France
DOI: https://doi.org/10.1080/21645515.2024.2334084
2024-04-03
Human Vaccines & Immunotherapeutics
Abstract:We conducted a national in-depth analysis including pharmacovigilance reports and clinical study to assess the reporting rate (RR) and to determine the clinical profile of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in COVID-19-vaccinated individuals. First, based on the French pharmacovigilance database, we estimated the RR of PMR and GCA cases in individuals aged over 50 who developed their initial symptoms within one month of receiving the BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines. We then conducted a nationwide survey to gather clinical profiles, therapeutic management, and follow-up data from individuals registered in the pharmacovigilance study. A total of 70 854 684 COVID-19 vaccine doses were administered to 25 260 485 adults, among which, 179 cases of PMR (RR 7. 1 cases/1 000 000 persons) and 54 cases of GCA (RR 2. 1 cases/1 000 000 persons) have been reported. The nationwide survey allowed the characterization of 60 PMR and 35 GCA cases. Median time to the onset of first symptoms was 10 (range 2–30) and 7 (range 2–25) days for PMR and GCA, respectively. Phenotype, GCA-related ischemic complications and -large vessel vasculitis as well as therapeutic management and follow-up seemed similar according to the number of vaccine shots received and when compared to the literature data of unvaccinated population. Although rare, the short time between immunization and the onset of first symptoms of PMR and GCA suggests a temporal association. Physician should be aware of this potential vaccine-related phenomenon.
immunology,biotechnology & applied microbiology